Abstract 5757: Graphene quantum dots-covered AuAg alloy nanoparticles as drug delivery platforms for anticancer applications
Authors: Bonilla Alondra Del Mar Veloz , Weiner Brad , Morell Gerardo , Medina-Berríos Nataniel 
Published: March 2024

Cancer continues to be a global health challenge, with millions suffering from its various forms. Prostate cancer, in particular, emerges as a significant health risk for men. Originating in the prostate gland—a small organ nestled in the male pelvis—this type of cancer the second most common cause of cancer-related deaths among men in the U.S. Despite numerous medical breakthroughs over the years, finding an effective treatment for prostate cancer remains a challenge. Our research is venturing into a new frontier in the fight against prostate cancer, focusing on an innovative method, it explores the potential of nanoparticles for targeted drug delivery. This targeted approach promises to not only intensify the therapeutic effect, but also minimize adverse side effects on healthy cells, ensuring a more balanced and effective treatment regimen. A key in this study is the drug Andrographolide (ADG), which has been previously recognized for its robust anti-cancer properties. However, one of its limitations is its hydrophobicity, which makes it challenging to administer due to solubility concerns. To navigate this challenge, we are pioneering the synthesis of AuAg (gold and silver) graphene quantum dots (GQDs) alloy nanoparticles. AuAg particles, in have been the subject of numerous studies due to their profound impact on cellular processes. By integrating a protective layer of GQDs, we aim to boost the nanoparticles' stability, all while preventing any potential release of harmful metallic ions. The primary objective of this advanced approach is to augment the solubility of andrographolide, paving the way for its targeted and efficient delivery to PC-3 cells. An integral part of our research involves determining the IC50 value, which is pivotal in indicating the concentration at which the drug can inhibit the growth of 50% of prostate cancer cells. Once the IC50 value for the AuAgGQDs is firmly established, our focus will shift to evaluating its effects on the morphology of Red Blood Cells (RBCs). By encapsulating andrographolide within the designed nanoparticles, such as AuAgGQDs and their derivatives, we aim to observe changes in morphology. If there is a change in morphology, it indicates successful drug encapsulation. Through this research, we are not just seeking a viable treatment method, but also aiming to expand the horizons of drug delivery systems. The insights gained from this study could very well revolutionize our understanding of therapeutic potential and underscore the importance of nanoparticles in the realm of biomedical applications.

Citation Format: Alondra Del Mar Veloz Bonilla, Brad Weiner, Gerardo Morell, Nataniel Medina-Berríos. Graphene quantum dots-covered AuAg alloy nanoparticles as drug delivery platforms for anticancer applications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5757.